A Residue in the S2 Subsite Controls Substrate Selectivity of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9*
暂无分享,去创建一个
[1] Jeffrey W. Smith,et al. A Unique Substrate Recognition Profile for Matrix Metalloproteinase-2* , 2002, The Journal of Biological Chemistry.
[2] J W Smith,et al. Substrate Hydrolysis by Matrix Metalloproteinase-9* , 2001, The Journal of Biological Chemistry.
[3] M. Hidalgo,et al. Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.
[4] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[5] Z. Werb,et al. The Serpin α1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo , 2000, Cell.
[6] I. Stamenkovic,et al. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.
[7] M. Radomski,et al. Differential Regulation of Platelet Aggregation by Matrix Metalloproteinases-9 and -2 , 1999, Thrombosis and Haemostasis.
[8] Timo Sorsa,et al. Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.
[9] G. Schneider,et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.
[10] J. Nemunaitis,et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] R. Steele,et al. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[12] R. Huber,et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 , 1997, Nature.
[13] G. Giannelli,et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.
[14] Y. Okada,et al. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. , 1997, The Biochemical journal.
[15] D. Corey,et al. Origins of the specificity of tissue-type plasminogen activator. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[16] P. Reinemer,et al. The metzincins — Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a super family of zinc‐peptidases , 1995, Protein science : a publication of the Protein Society.
[17] R. Huber,et al. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. , 1995, European journal of biochemistry.
[18] R. Huber,et al. The X‐ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. , 1994, The EMBO journal.
[19] A M Hassell,et al. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. , 1994, Science.
[20] H. Birkedal‐Hansen,et al. Comparative sequence specificities of human 72- and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin). , 1993, Biochemistry.
[21] H. Birkedal‐Hansen,et al. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[22] Z. Werb,et al. How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.
[23] S. Zucker,et al. Inhibition of matrix metalloproteinases : therapeutic applications , 1999 .
[24] T. Kreis,et al. Guidebook to the extracellular matrix, anchor, and adhesion proteins , 1999 .
[25] W. A. Galloway,et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. , 1998, British journal of clinical pharmacology.
[26] H. Birkedal‐Hansen,et al. Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[27] H. Birkedal‐Hansen,et al. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.